<?xml version="1.0" encoding="UTF-8"?>
<p>Currently, medicinal plants represent the source of more than 25% of drugs officially approved by the Food and Drug Administration (FDA) and the European Medicinal Agency (EMA) for the development of novel synthetic drugs [
 <xref rid="B128-pharmaceuticals-13-00444" ref-type="bibr">128</xref>]. Their derived by-products account for the 75â€“90% of the total used in the primary healthcare systems of economically developed nations [
 <xref rid="B129-pharmaceuticals-13-00444" ref-type="bibr">129</xref>]. However, only 6% of the plants have been studied from the pharmacological point of view and for 85% of them their phytochemical potential has not been evaluated [
 <xref rid="B130-pharmaceuticals-13-00444" ref-type="bibr">130</xref>], which represents a vast territory of families of plants with medicinal properties unexplored, such as 
 <italic>Bryophyllum</italic> sp. Novel strategies, based on plant biotechnology methodologies, are required to meet the growing global demand for products derived from medicinal plants for industrial purposes in different sectors, such as the food, cosmetic, and pharmaceutical industries [
 <xref rid="B131-pharmaceuticals-13-00444" ref-type="bibr">131</xref>].
</p>
